Jaime Jimenez, MD
Ophthalmology · Hattiesburg, MSNPI 1932102951
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Alimera Sciences, Inc. at 37.5% of the total. Reporting peaked in 2021 at $3,793 and has fallen 74.7% since, to $959 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $50.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$5K
- Novartis$3K
- AbbVie$2K
- Apellis Pharmaceuticals, Inc.$622
- Bausch & Lomb Americas Inc.$325
- Genentech USA, Inc.$256
- plus $1K from 15 others
Across 1 payment — averaging $10,725 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$11K
What the payments were for
- Consulting fees$3,20025%
- Speaking & faculty fees$3,50028%
- Food & beverage$5,82046%
- Education$891%
- Entertainment$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 52 | $4,741 |
| Novartis | 8 | $3,300 |
| AbbVie(2 entities) | 99 | $1,949 |
| Apellis Pharmaceuticals, Inc. | 19 | $622 |
| Bausch & Lomb Americas Inc. | 8 | $325 |
| Genentech USA, Inc. | 7 | $256 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $252 |
| ANI Pharmaceuticals, Inc. | 12 | $185 |
| Coherus Oncology, Inc. | 7 | $169 |
| Regeneron Healthcare Solutions, Inc. | 7 | $167 |
| Mallinckrodt Hospital Products Inc. | 3 | $137 |
| Alcon | 3 | $108 |
| Glaukos Corporation | 4 | $74 |
| Aerie Pharmaceuticals, Inc. | 4 | $66 |
| NEW World Medical,inc. | 1 | $65 |
| Astellas Pharma US Inc | 3 | $60 |
| Topcon Healthcare Solutions, Inc. | 1 | $42 |
| Sandoz | 2 | $39 |
| Harrow Eye, LLC | 1 | $36 |
| Opsens Inc. | 2 | $30 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,639 in reported general payments places this provider in the 90th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 531 | $22,954 |
| RestasisCyclosporine | 15 | $12,684 |
| LumiganBimatoprost | 33 | $11,822 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 497 | $9,147 |
| Latanoprost | 1,201 | $8,650 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $7,492 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 29 | $7,359 |
| Brimonidine Tartrate | 544 | $6,898 |
| VyzultaLatanoprostene Bunod | 19 | $6,652 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $5,933 |
| Ketorolac Tromethamine | 230 | $5,548 |
| Alphagan PBrimonidine Tartrate | 16 | $4,274 |
| Ciprofloxacin Hcl | 268 | $3,103 |
| Atropine Sulfate | 48 | $2,823 |
| Dorzolamide Hcl | 136 | $2,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,949 | $36,27283 claims |
| AlconSimbrinza | $108 | $7,35929 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $325 | $6,65219 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $66 | $5,93317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Hattiesburg
- Kiper NelsonHattiesburg$234K
- Adam QuinnHattiesburg$29K
- Wade TuckerHattiesburg$4K
- Stoney WilliamsonHattiesburg$3K
- Charles RichardsonHattiesburg$3K
- Todd WilliamsonHattiesburg$3K
- Benjamin PaceHattiesburg$3K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.